OK-432 Suppresses Proliferation and Metastasis by Tumor Associated Macrophages in Bladder Cancer

  • Tian, Yuan-Feng (Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Tang, Kun (Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Guan, Wei (Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Yang, Tao (Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Xu, Hua (Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Zhuang, Qian-Yuan (Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Ye, Zhang-Qun (Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology)
  • Published : 2015.06.26


OK-432, a Streptococcus-derived anticancer immunotherapeutic agent, has been applied in clinic for many years and achieved great progress in various cancers. In the present study, we investigated its anticancer effect on bladder cancer through tumor associated macrophages (TAMs). MTS assay validated OK-432 could inhibit proliferation in both T24 and EJ bladder cell lines. OK-432 also induced apoptosis of bladder cancer cells in vitro. Consequently, we demonstrated that OK-432 could suppress the bladder cancer cells migration and invasion by altering the EMT-related factors. Furthermore, using SD rat model, we revealed that OK-432 inhibited tumor growth, suppressed PCNA expression and inhibited metastasis in vivo. Taken together, these findings strongly suggest that OK-432 inhibits cell proliferation and metastasis through inducing macrophages to secret cytokines in bladder cancer.


OK-432;bladder cancer;proliferation;apoptosis;TAMs


  1. Allavena P, Mantovani A (2012). Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol, 167, 195-205.
  2. Ayari C, LaRue H, Hovington H, et al (2009). Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy. Eur Urol, 55, 1386-95.
  3. Bazzoni F, Beutler B (1996). The tumor necrosis factor ligand and receptor families. N Engl J Med, 334, 1717-25.
  4. Biddle A, Mackenzie IC (2012). Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev. [Epub ahead of print].
  5. Bonde AK, Tischler V, Kumar S, et al (2012). Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer, 12, 35.
  6. Daigneault M, Preston JA, Marriott HM, et al (2010). The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One, 5, 8668.
  7. Fujimoto T, Duda RB, Szilvasi A, et al (1997). Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J Immunol, 158, 5619-26.
  8. Javle MM, Gibbs JF, Iwata KK, et al (2007). Epithelialmesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol, 14, 3527-33.
  9. Lin CY, Lin CJ, Chen KH, et al (2006). Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction. FEBS Lett, 580, 3042-50.
  10. Liu WF, Ji SR, Sun JJ, et al (2012). CD146 expression correlates with epithelial-mesenchymal transition markers and a poor prognosis in gastric cancer. Int J Mol Sci, 13, 6399-406.
  11. Liu ZG (2005). Molecular mechanism of TNF signaling and beyond. Cell Res, 15, 24-7.
  12. Mantovani A, Allavena P, Sica A, et al (2008). Cancer-related inflammation. Nature, 454, 436-44.
  13. Mantovani A, Germano G, Marchesi F, et al (2011). Cancerpromoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol, 41, 2522-5.
  14. Nakamoto Y, Mizukoshi E, Kitahara M, et al (2011). Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Clin Exp Immunol, 163, 165-77.
  15. Newton MR, Askeland EJ, Andresen ED, et al (2014). Antiinterleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guerin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity. Clin Exp Immunol, 177, 261-8.
  16. Oshimi K, Kano S, Takaku F, et al (1980). Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. J Natl Cancer Inst, 65, 1265-9.
  17. Ploeg M, Aben KK, Kiemeney LA (2009). The present and future burden of urinary bladder cancer in the world. World J Urol, 27, 289-93.
  18. Qian BZ, Pollard JW (2010). Macrophage diversity enhances tumor progression and metastasis. Cell, 141, 39-51.
  19. Saito M, Ebina T, Koi M, et al (1982). Induction of interferongamma in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenes. Cell Immunol, 68, 187-92.
  20. Sato T, Terai M, Tamura Y, et al (2011). Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res, 51, 170-82.
  21. Schenk-Braat EA, Bangma CH (2005). Immunotherapy for superficial bladder cancer. Cancer Immunol Immunother, 54, 414-23.
  22. Tano T, Okamoto M, Kan S, et al (2013). Immunochemoradiotherapy for patients with oral squamous cell carcinoma: augmentation of OK-432-induced helper T cell 1 response by 5-FU and X-ray irradiation. Neoplasia, 15, 805-14.
  23. Tano T, Okamoto M, Kan S, et al (2012). Growth inhibition and apoptosis by an active component of OK-432, a streptococcal agent, via Toll-like receptor 4 in human head and neck cancer cell lines. Oral Oncol, 48, 678-85.
  24. Wada H, Isobe M, Kakimi K, et al (2014). Vaccination with NYESO- 1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. J Immunother, 37, 84-92.
  25. Wu KJ, Zeng J, Zhu GD, et al (2009). Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacol Sin, 30, 1162-8.
  26. Yamaguchi Y, Miyahara E, Ohshita A, et al (2003). Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+Th1 killer lymphocytes. Br J Cancer, 89, 1876-84.
  27. Yoo C, Do HA, Jeong IG, et al (2010). Efficacy of dendritic cells matured early with OK-432 (Picibanil), prostaglandin E2, and interferon-alpha as a vaccine for a hormone refractory prostate cancer cell line. J Korean Med Sci, 25, 1284-90.
  28. Zhang P, Jin YF, Zhang Q, et al (2014). Macrophages promote coal tar pitch extract-induced tumorigenesis of BEAS-2B cells and tumor metastasis in nude mice mediated by AP-1. Asian Pac J Cancer Prev, 15, 4871-6.
  29. Zhang QW, Liu L, Gong CY, et al (2012). Prognostic significance of tumor-associated macrophages in solid tumor: a metaanalysis of the literature. PLoS One, 7, 50946.

Cited by

  1. Polycationic carbosilane dendrimer decreases angiogenesis and tumor-associated macrophages in tumor-bearing mice vol.5, pp.126, 2015,
  2. Effects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancer vol.13, pp.6, 2017,